Cell-mediated irnmunosuppression in pregnancy and in women taking oral contraceptives has been described.1 2 Temporary remission of autoimmune thyroid disease with postpartum recurrence has also been reported associated with the gradual reduction of serum antithyroid antibody titres as the pregnancy progressed, followed by a postpartum increase reaching a peak three to four months after delivery.3
Study and results
Thyroid diseases were analysed as part of a continuing major prospective survey of oral contraceptives. The study began in 1968. About 23 000 women currently taking a contraceptive pill and a similar number of controls who had never taken an oral contraceptive were recruited by 1400 general practitioners over a period of 14 months. Observations of subsequent morbidity and other relevant data of this population formed the basis for our analyses. The design of the study and the interpretation of the findings have been described elsewhere.4
The main findings are shown in the table. Because of the close interrelationship of thyroid disorders we analysed only the frequency of reporting of the first diagnosis during the study of any thyroid disease in one patient. Cases first diagnosed during pregnancy were excluded together with the associated periods of observations. Patients were categorised according to their contraceptive status at the time of diagnosis as (1) takers (those currently taking an oral contraceptive who had had no break in use longer than one cycle); (2) ex-takers (those who had formerly used oral contraceptives); and (3) controls (those who had never used oral contraceptives). All three clinical groups of thyroid disease were reported less frequently in takers than in controls. In patients with euthyroid swelling the rate in takers was 69 'O of that in controls, and the proportions for thyrotoxicosis and myxoedema were 71 %/1 and 57 ON respectively. Although these differences taken separately do not reach statistical significance, the frequency of reporting in takers was consistently materially less than in controls. When the subcategories are combined the risk ratio of 0-68 becomes highly significant (P< 001; 950% confidence limits 0-52 to 0 85). An important finding was that the rates for thyroid disease in ex-takers did not differ from controls. The frequency of reporting of thyroid disease showed no correlation with age, parity, cigarette consumption, or social class in any of the contraceptive categories, and reporting rates did not correlate with oestrogen or progestogen dosage or with the duration of use of oral contraceptives.
Comment
These results suggest that oral contraceptives exert a protective effect against thyroid disease. In our interim report4 we assessed the probable biases in a prospective study of this type. Selection bias was substantially avoided by excluding all women who had had the disease before recruitment. Other forms of bias generally operate in the one direction, giving an estimated 20% overreporting in the takers and a tendency to exaggerate adverse reactions to oral contraceptives and underassess beneficial effects. Our findings of a higher rate of reporting of thyroid disease in controls than takers is contrary to the expected effect of these biases. The finding that the frequency of thyroid disease in ex-takers is not materially different from the controls suggests that there is no residual protective effect against thyroid disease after the contraceptive has been stopped. Our observations suggest that the effect of oral contraceptives on thyroid disease may be associated with preventing or retarding autoimmune processes. The reduced incidence of rheumatoid arthritis5 in oral contraceptive takers probably has a similar mechanism. In absolute terms the protective effect against thyroid disease would be as small as 1 in 1600 oral contraceptive users a year. The observation, however, may contribute to an understanding of the mechanism of action of oral contraceptives and the aetiology of thyroid disease.
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Case report
This 18-year-old, single, West Indian Negro primigravida had her last menstrual period in May 1975 and was seen in the ante-natal clinic in January 1976 in the 36th week of gestation. She had had no previous antenatal care.
Her history showed that she had been treated for Wilms's tumour of her right kidney. In 1970, when she was 12, she was admitted to Queen Elizabeth Hospital for Children, London, with a mass on her right flank, and the right kidney was removed. A tumour weighing 1 kg was found, which was shown to be a nephroblastoma. There was no spread beyond the kidney and no obvious lymph node or renal vein metastases. After operation she was given a course of actinomycin D followed by cobalt teletherapy at St Bartholomew's Hospital. A mid-plane dose of 3500 rads was given over five weeks to the right renal bed and para-aortic nodes. No other chemotherapy was given, and she subsequently remained well.
On booking into our unit she appeared to be a well developed, healthy teenager. She was 167-6 cm tall, weighed 56-7 kg, and had blood pressure of 105/60 mm Hg and pulse rate of 76 beats/min. A nephrectomy scar was present. The size of her uterus corresponded to the period of amenorrhoea. 
